此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

OCU500(编码SARS-CoV-2刺突蛋白的ChAd36载体疫苗)经鼻内和吸入途径在已接种疫苗成人中的安全性和免疫原性试验

OCU500(ChAd36载体编码SARS-CoV-2刺突蛋白)作为下一代SARS-CoV-2加强疫苗,在已接种疫苗的成人中经鼻内和吸入途径进行的1期开放标签安全性及免疫原性试验

This phase 1 randomized, open-label, dose-escalation clinical trial evaluates the safety and immunogenicity of OCU500, a ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine, in healthy adults aged 18-64 who previously completed a primary COVID-19 vaccination series and at least one booster. The study evaluates two dose levels (1×10^10 viral particles (VP) and 5×10^10 VP) and two routes of administration (intranasal and inhaled). The trial includes 80 participants across four study arms (20 per arm). The primary objective is to evaluate the safety and reactogenicity of a single dose of OCU500 administered in previously vaccinated healthy adults.

研究概览

地位

主动,不招人

条件

干预/治疗

详细说明

This phase 1 randomized, open-label, dose-escalation clinical trial evaluates the safety and immunogenicity of OCU500, a ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine, in healthy adults aged 18-64 who previously completed a primary COVID-19 vaccination series and at least one booster. The study evaluates two dose levels (1×10^10 viral particles (VP) and 5×10^10 VP) and two routes of administration (intranasal and inhaled). The trial includes 80 participants across four study arms (20 per arm). The primary objective is to evaluate the safety and reactogenicity of a single dose of OCU500 administered in previously vaccinated healthy adults. Secondary objectives include evaluating systemic anti-Spike humoral responses, nasal mucosal Immunoglobulin A (IgA) and Immunoglobulin G (IgG) responses, and immune responses toward vectors.

研究类型

介入性

注册 (实际的)

83

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Georgia
      • Decatur、Georgia、美国、30030-1705
        • The Hope Clinic of Emory University
    • Maryland
      • Baltimore、Maryland、美国、21201-1509
        • University of Maryland, School of Medicine, Center for Vaccine Development and Global Health
    • Massachusetts
      • Boston、Massachusetts、美国、02115-6110
        • Brigham and Women's Hospital
    • Missouri
      • St Louis、Missouri、美国、63104-1015
        • Saint Louis University Center for Vaccine Development
    • Texas
      • Galveston、Texas、美国、77555-0435
        • University of Texas Medical Branch

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 64年 (成人)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Provides written informed consent before initiation of any study procedures.

  2. Able to understand and agree to comply with planned study procedures and be available for all study visits.

  3. Non-pregnant adults, 18 through 64 years of age at the time of study product administration.

  4. Participants of childbearing potential* must agree to use or have practiced true abstinence** or use at least one acceptable primary form of contraception.***

    *These criteria apply to females who are in a heterosexual relationship and are of childbearing potential. Not of childbearing potential include post-menopausal females (defined as having a history of amenorrhea for at least one year) or a documented status as being surgically sterile (hysterectomy, bilateral oophorectomy, or tubal ligation/salpingectomy).

    **True abstinence is 100 percent of the time, no sexual intercourse (penis enters the vagina). Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods.

    ***Acceptable forms of primary contraception include a monogamous relationship with a vasectomized partner who has been vasectomized for 180 days or more before the participant's study product administration, a copper intrauterine device, a levonorgestrel-releasing intrauterine device, a progestin-only oral contraceptive pill, a depot medroxyprogesterone injection, or a progestin implant. Combined hormonal contraceptives containing estrogen, including combined oral contraceptive pills, transdermal patches, and vaginal rings, are not acceptable for this trial. Must have used at least one acceptable primary form of contraception for at least 30 days before study product administration and agree to continue at least one acceptable primary form of contraception through 60 days after study product administration.

  5. Participants of childbearing potential must have a negative urine pregnancy test at screening and within 24 hours before study product administration.

  6. In general, good health.*

    *As determined by medical history and physical examination, including vital signs, to evaluate acute or ongoing chronic medical diagnoses/conditions that have been present for at least 90 days, which would affect the assessment of participant safety. Chronic medical diagnoses/ conditions should be stable for the last 30 days (i.e., no hospitalization, ER, or urgent care for the condition). This includes no change in chronic prescription medication, dose, or frequency due to deterioration of the chronic medical diagnosis or condition within the 30 days preceding the study product administration. Any prescription change that is due to a change of health care provider, insurance company, etc., or done for financial reasons, and in the same class of medication, will not be considered a deviation of this inclusion criterion. Participants may be on chronic or as-needed (prn) medications if, in the opinion of the participating site PI or appropriate sub-investigator, they pose no additional risk to participant safety or assessment of reactogenicity and immunogenicity.

  7. Receipt of a complete primary COVID-19 vaccine series and at least one booster* with last vaccination at least 16 weeks before study product administration.

    *Booster may be either homologous or heterologous to the primary vaccine series. It must be an FDA-authorized/licensed vaccine, though doses may have been received as part of a clinical trial.

  8. Clinical screening laboratory evaluations are within normal reference ranges or grade 1 with no clinical significance (NCS) per investigator discretion.*

    *(White Blood Cells [WBCs] with differential [diff], hemoglobin [Hgb], platelets [PLTs], PTT, PT, Alanine Transaminase [ALT], Aspartate Transaminase [AST], Creatinine [Cr], Alkaline Phosphatase [ALP], Total Bilirubin [T. Bili]). ALT, AST, ALP, T. Bili, and creatinine values that are below the reference range will not be exclusionary, as these values below the reference range are clinically insignificant.

  9. Must agree to have samples stored for secondary research.

  10. Must complete a Test of Understanding (ToU) before enrollment by answering 90 percent of questions correctly at least once in 3 attempts.

Exclusion Criteria:

  1. Positive SARS-CoV-2 PCR at screening.

  2. Abnormal vital signs (Grade 1 or higher).*

    *Grade 1 or higher is equivalent to: Systolic blood pressure (SBP) = 141 mmHg or = 89 mmHg Diastolic blood pressure (DBP) = 91 mmHg Heart rate (HR) is = 101 beats per minute or = 54 beats per minute Oral temperature = 38.0 degrees Celsius (100.4 degrees Fahrenheit)

  3. History of SARS-CoV-2 infection within the prior 16 weeks OR receipt of any COVID-19 vaccine within the prior 16 weeks before study product administration.

  4. Participant who is pregnant or breastfeeding or less than 12 weeks post partum at the time of study product administration.

  5. Participant has donated blood or plasma within 4 weeks prior to study product administration, or does not agree to refrain from blood or plasma donation until Day 181.

  6. Receipt of antibody or blood-derived products within 90 days before study product administration.

  7. Any significant medical or psychiatric diseases or any other condition that, in the opinion of the site PI or appropriate sub-investigator, precludes study participation.*

    *Significant self-reported or medically reported medical or psychiatric conditions include, but are not limited to drug or alcohol abuse within 6 months of enrollment, significant kidney disease, liver disease, history of hematologic malignancies, ongoing malignancy or recent diagnosis of malignancy in the last five years, excluding treated basal cell and squamous cell carcinoma of the skin, and cervical carcinoma in situ, which are allowed.

  8. Any respiratory disease, including but not limited to chronic obstructive pulmonary disease (COPD), asthma, interstitial lung disease, bronchiectasis, etc.

  9. Neurological or neurodevelopmental conditions.*

    *These conditions include: history of Bell's palsy, history of four or more migraine headaches in the past 12 months that interfered with normal daily activity or any migraine headache in the past 5 years that required emergency or inpatient medical care, epilepsy, seizures in the last 5 years, encephalopathy, focal neurologic deficits, Guillain-Barré syndrome, myelopathy, peripheral neuropathy, encephalomyelitis, transverse myelitis, stroke or transient ischemic attack, multiple sclerosis, Parkinson's disease, amyotrophic lateral sclerosis, Creutzfeldt-Jakob disease, or Alzheimer's disease.

  10. Cardiovascular disease (e.g., congestive heart failure, cardiomyopathy, ischemic heart disease), including any history of myocarditis or pericarditis, or uncontrolled cardiac arrhythmia.

  11. Any autoimmune disease, including hypothyroidism without a defined non-autoimmune cause.

  12. Any significant nasal or upper airway disease.*

    *Including, but not limited to, being prone to epistaxis, a history of inflammatory rhinitis (including allergic rhinitis) that requires daily medications, cochlear implants, head/neck radiation history, anosmia/dysosmia, conditions that require prescription or over the counter intranasal medication (intermittent use will be allowed if no use occurred for 30 days before study product administration and participant agrees to not use intranasal medication (other than steroids) for 30 days after study product administration and to not use intranasal steroids for 6 months after study product administration), and certain ear, nose and throat (ENT) conditions, including significant upper airway/nasopharyngeal disease or abnormal anatomy such as CSF leak.

  13. Has an acute illness, as determined by the site Principal Investigator or appropriate sub-investigator within 72 hours before study product administration.*

    *An acute illness which is nearly resolved with only minor residual symptoms remaining is allowable if, in the opinion of the participating site PI or appropriate sub-investigator, the residual symptoms will not interfere with the ability to assess safety parameters as required by the protocol.

  14. Has a positive test result for hepatitis B surface antigen, hepatitis C virus RNA (by reflex testing), or human immunodeficiency virus (HIV) antigen/antibody test at screening.

  15. Has any confirmed or suspected immunosuppressive or immunodeficient state, such as asplenia, recurrent severe infections, and chronic* immunosuppressant medication within the past 6 months.**

    *Chronic meaning more than 14 continuous days.

    **Ophthalmic and topical steroids are allowed, see exclusions 12 and 21 for intranasal steroids.

  16. Has received any investigational product within 60 days, or 5 half-lives, whichever is longer, before study product administration; or is planning to receive one during the study.

  17. Has a history of hypersensitivity or severe allergic reaction* to any previous licensed or unlicensed vaccine or to the candidate vaccine components.

    *e.g., anaphylaxis, generalized urticaria, angioedema, other significant reaction

  18. History of chronic idiopathic urticaria.

  19. Received or plans to receive licensed inactivated/subunit vaccine within 14 days of study product administration or live vaccine within 28 days of study product administration.

  20. Plan to receive a COVID-19 vaccine within the 180 days following study product administration.

  21. Regular use of intranasal medications, including steroids.*

    *Participant must have had no intranasal medication use for 30 days before study product administration and plans not to use intranasal medications for 30 days after study product administration for medications other than steroids, and for 6 months after study product administration for intranasal steroids (including over-the-counter fluticasone).

  22. History of smoking within three months before enrollment.*

    *Including cigarettes, smokeless and other tobacco products, e-cigarettes (to include vaping and Juuling products), marijuana, nicotine gum, and nicotine lozenges.

  23. Use of intranasal illicit drugs in the 5 years before study product administration or plans to use during the study.

  24. Planned international travel between study product administration and Day 29.

  25. Previous receipt of any adenovirus-vector vaccine by the intranasal or aerosol routes.

  26. Bleeding disorder (e.g., factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following Intramuscular injections or venipuncture.

  27. Recent (within 3 months of study product administration): major surgery, >=3 days immobility, chronic infection, or head trauma that may increase thrombosis risk.*

    *Major surgery is either abdominal or vascular, or orthopedic surgery, and immobility implies bed rest.

  28. History of venous or arterial thrombosis or any known thrombophilic condition, including heparin-induced thrombocytopenia (HIT) or thrombosis.

  29. BMI >/= 40kg/m^2

  30. Current/planned systemic estrogen therapy, except stable transdermal estradiol, from 30 days pre-dose through end of study participation. Low-dose vaginal estrogen is permitted.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:预防
  • 分配:随机化
  • 介入模型:顺序分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Arm 1

A single dose of 1×10^10 viral particles (VP) in 100 uL of OCU500 administered via inhalation on Day 1 in participants from 18 to 64 years of age. N = 20

OCU500 is a monovalent, replication-defective, chimpanzee adenovirus (ChAd36)-vectored COVID-19 vaccine that encodes a codon-optimized, stabilized prefusion form of the spike (S) protein from the Omicron XBB1.5 strain.

实验性的:Arm 2

A single dose of 1×10^10 viral particles (VP) in 100 uL of OCU500 administered intranasally (0.05 mL/nostril) on Day 1 in participants from 18 to 64 years of age. N = 20

OCU500 is a monovalent, replication-defective, chimpanzee adenovirus (ChAd36)-vectored COVID-19 vaccine that encodes a codon-optimized, stabilized prefusion form of the spike (S) protein from the Omicron XBB1.5 strain.

实验性的:Arm 3

A single dose of 5x10^10 viral particles (VP) in 100 uL of OCU500 administered via inhalation on Day 1 in participants from 18 to 64 years of age. N = 20

OCU500 is a monovalent, replication-defective, chimpanzee adenovirus (ChAd36)-vectored COVID-19 vaccine that encodes a codon-optimized, stabilized prefusion form of the spike (S) protein from the Omicron XBB1.5 strain.

实验性的:Arm 4

A single dose of 5x10^10 viral particles (VP) in 100 uL of OCU500 administered intranasally (0.05 mL/nostril) on Day 1 in participants from 18 to 64 years of age. N = 20

OCU500 is a monovalent, replication-defective, chimpanzee adenovirus (ChAd36)-vectored COVID-19 vaccine that encodes a codon-optimized, stabilized prefusion form of the spike (S) protein from the Omicron XBB1.5 strain.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
异常临床安全实验室不良事件(AE)的发生。
大体时间:在第8天
在第8天
特别关注不良事件(AESI)的发生情况。
大体时间:研究产品给药后6个月内
研究产品给药后6个月内
需要医疗干预的不良事件(MAAEs)的发生情况。
大体时间:研究产品给药后6个月内
研究产品给药后6个月内
新发慢性病(NOCMCs)的发生情况。
大体时间:研究产品给药后6个月内
研究产品给药后6个月内
严重不良事件(SAEs)的发生情况。
大体时间:研究产品给药后6个月内
研究产品给药后6个月内
主动征集局部不良事件(AEs)的发生情况。
大体时间:至第8天
至第8天
征集性全身性不良事件(AEs)的发生情况。
大体时间:至第8天
至第8天
非请求不良事件(AEs)的发生情况。
大体时间:截至第29天
截至第29天

次要结果测量

结果测量
大体时间
抗载体抗体水平
大体时间:第1天至第91天
第1天至第91天
SARS-CoV-2 抗刺突蛋白鼻黏膜结合免疫球蛋白 A (IgA)
大体时间:第1天至第181天
第1天至第181天
SARS-CoV-2 抗刺突蛋白鼻黏膜结合免疫球蛋白 G (IgG)
大体时间:第1天至第181天
第1天至第181天
SARS-CoV-2 抗刺突蛋白血清结合免疫球蛋白 A (IgA) 抗体
大体时间:第1天至第181天
第1天至第181天
SARS-CoV-2 抗刺突蛋白血清结合免疫球蛋白G(IgG)抗体
大体时间:第1天至第181天
第1天至第181天
SARS-CoV-2 抗刺突血清中和抗体
大体时间:第1天至第181天
第1天至第181天

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年5月26日

初级完成 (估计的)

2027年4月29日

研究完成 (估计的)

2027年11月1日

研究注册日期

首次提交

2026年4月10日

首先提交符合 QC 标准的

2026年4月10日

首次发布 (实际的)

2026年4月17日

研究记录更新

最后更新发布 (实际的)

2026年11月13日

上次提交的符合 QC 标准的更新

2026年11月12日

最后验证

2026年4月14日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅